Cancer Biomarkers Market

Cancer Biomarkers Industry Worth $42.0 billion by 2029, with a CAGR of 11.3%

The report "Cancer Biomarkers Market by Profiling Technology (Omics, Imaging), Cancer (Lung, Breast, Leukemia, Melanoma, Colorectal), Product (Instruments, Consumables), Application (Diagnostics, R&D, Prognostics), Enduser, and Region - Global Forecast to 2029", is projected to reach USD 42.0 billion by 2029 from USD 24.5 billion in 2024, at a CAGR of 11.3% during the forecast period.

Browse 364 market data Tables and 53 Figures spread through 338 Pages and in-depth TOC on "Cancer Biomarkers Market by Profiling Technology (Omics, Imaging), Cancer (Lung, Breast, Leukemia, Melanoma, Colorectal), Product (Instruments, Consumables), Application (Diagnostics, R&D, Prognostics), Enduser, and Region - Global Forecast to 2029"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/oncology-biomarkers-202.html

Increasing incidence of cancer followed by awareness for early diagnosis, growing investments in research and development of cancer biomarkers, extensive use of these biomarkers for diagnosis, drug discovery and development are the key factors responsible for growth of this market. Companies in the market for cancer biomarkers are finding that developing nations like China, Japan, and India provide attractive opportunities.

According to the profiling technology segment, the omics technology held the biggest market share for cancer biomarkers.

The market for cancer biomarkers has been divided into two segments based on profiling methods: omics technologies and imaging technologies. As of 2023, the cancer biomarkers market was dominated by the omics technology segment, mainly due to high throughput nature of these technologies in cancer biomarker discovery and diagnosis.

Throughout the projection period, the breast cancer segment is expected to develop at the fastest rate.

The market for cancer biomarkers is divided into categories according to the kind of cancer: non-Hodgkin's lymphoma, kidney cancer, bladder cancer, thyroid cancer, breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, leukemia, thyroid cancer, and other cancer types. The market for cancer biomarkers was dominated in 2023 by the breast cancer segment. The huge share of this segment is due to the growing rate of breast cancer cases worldwide followed by awareness for  diagnosis for prevention and treatment.

The instruments segment held the largest share in the market, by product”.

The cancer biomarker market is divided into three segments based on product: instruments, consumables, and bioinformatics software. In 2023, the instruments segment hold the major market due to continuous need for cancer detection, improvements in instrument technology and high accuracy detection methods .

By application category, the cancer biomarkers market held the biggest share in 2023 for the diagnostics segment.

The market for cancer biomarkers has been divided into segments based on application, including risk assessment, prognostics, diagnostics, and research & development. As of 2023, the cancer biomarkers market was dominated by the diagnostics sector, primarily due to the increase in cancer incidence, increased awareness and acceptance of diagnostic tests and increase in technologically advanced biomarker products.

“North America aimed for the largest share of the cancer biomarkers market”.

The global cancer biomarkers market is segmented into six major regions—North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa and GCC Countries. North America is the largest regional market for cancer biomarkers. The large share of North America in this market can be attributed to the increasing prevalence of cancer, increasing research on cancer biomarkers, technological advancements, and the increasing use of cancer biomarkers in drug discovery and development.

The major players leading in cancer biomarkers market are F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific, Inc. (US), QIAGEN N.V. (Netherlands), Illumina, Inc. (US), Bio-Rad Laboratories, Inc. (US), Abbott Laboratories (US), bioMérieux SA (US), Becton, Dickinson and Company (US), Merck Millipore (US), Agilent Technologies (US), Myriad Genetics, Inc. (US), Sysmex Corporation (Japan), Hologic, Inc. (US), Quest Diagnostics (US), Centogene N.V. (Germany).

Don’t miss out on business opportunities in Cancer Biomarkers Market. Speak to our analyst and gain crucial industry insights that will help your business grow.

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]

Cancer Biomarkers Market Size,  Share & Growth Report
Report Code
MD 5627
PR Published ON
4/29/2024
Choose License Type
BUY NOW
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Cancer Biomarkers Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status
...

Digital Virtual Assistant - MarketsandMarkets

Home